The Result of Cisplatin-Based Neoadjuvant Chemotherapy in Patients Diagnosed With Non-Squamous Cell Carcinoma of the Cervix in Stage Ib2 to Iib: A Retrospective Cohort Study Publisher



A Mousavi AZAMOSADAT ; M Azadehrah MALIHE ; M Modarresgilani MITRA ; S Akhavan SETARE ; S Sheikh Hasani SHAHRZAD ; M Azadehrah MAHBOOBEH
Source: International Journal of Women's Health and Reproduction Sciences Published:2025

Abstract

Objectives: Neoadjuvant chemotherapy is one of the most important and prevalent therapeutic strategies to reduce complications and mortality in patients with cervical carcinoma. Due to the higher pathologic prevalence of squamous cell carcinoma (SCC) than non-SCC of the cervix, effective therapeutic strategies have been mostly proposed in relation to the pathology of cervical SCC and, therefore, there is insufficient evidence suggesting treatment recommendations on the pathology of non-SCC of the cervix. Thus, this study aimed to investigate the outcome of cisplatin-based neoadjuvant chemotherapy with Taxol in patients diagnosed with non-SCC of the cervix in stage IB2-IIB. Materials and Methods: This study was a retrospective cohort study conducted on patients with non-SCC of the cervix. Patients treated with cisplatin-based neoadjuvant chemotherapy + paclitaxel were evaluated for the results and outcomes of neoadjuvant chemotherapy based on the inclusion criteria. Data were statistically analyzed using SPSS software as well as performing Kaplan-Meier procedure and the log-rank test. Results: The mean age of the studied cases was 44.9. Tumor size after neoadjuvant chemotherapy was less than 4 cm in six cases. Tumor spread to the inner and outer half of the stroma was observed in most cases. Tumor spread to the lymph node section was observed in seven cases. Three cases showed parametric involvement, and eight cases showed pelvic lymph node involvement. Complete response to treatment was recorded in two cases (16.7%), partial response was found in six cases (50%), and stable disease was seen in one case (21.7%). The average time of disease-free survival and progression-free survival in patients was 77 months, which demonstrated no significant difference (P = 0.30). Conclusions: Neoadjuvant chemotherapy in cases of non-SCC of the cervix as well as SCC of the cervix produced a strong anti-tumor and inhibitory effect in our study. © 2025 Elsevier B.V., All rights reserved.